PRISM MEDICO AND PHARMACY LTD. - 512217 - Investor Complaints As Per Regulation 13(3) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
With reference to the above captioned subject report on investor complaints for the quarter ended 31st March, 2023 is attached herewith. You are requested to kindly take the same on your record and acknowledge receipt. PRISM MEDICO AND PHARMACY LTD. - 512217 - Non-Applicability Of Regulation 27 On Corporate Governance Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Ended 31St March, 2023.
Dear Sir / Madam, With reference to the above captioned subject it is hereby informed that the provisions of Regulation 27 on Corporate Governance of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 are not applicable on the company for the quarter ended 31st March, 2023. You are requested to kindly take the same on your record and acknowledge receipt. Thanking You. PRISM MEDICO AND PHARMACY LTD. - 512217 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 we hereby furnish a copy of compliance certificate issued by the RTA for the quarter ended 31st March, 2023. You are requested to kindly take the same on your record and acknowledge receipt. Thanking You. PRISM MEDICO AND PHARMACY LTD. - 512217 - Compliance-57 (5) : intimation after the end of quarter
Pursuant to Regulation 57(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR), we hereby confirm that the company has not issued any non-convertible securities. Therefore, there were no interest/dividend/principal obligations which were due for payment during the quarter 01st January, 2023 to 31st March, 2023. You are requested to kindly take the same on your record and acknowledge receipt. PRISM MEDICO AND PHARMACY LTD. - 512217 - Closure of Trading Window
Pursuant to Code of Conduct to regulate, monitor and report Trading by Insiders ('Code') and applicable SEBI Regulations, we would like to inform you that trading window for dealing in securities of the company by insiders stands closed from April 01, 2023 and will be re-opened 48 hours after the declaration of the financial results for the quarter and financial year ended March 31, 2023 to the Stock Exchanges. You are requested to kindly take the same on your record and acknowledge receipt. Thanking You. PRISM MEDICO AND PHARMACY LTD. - 512217 - Post Offer Advertisement
Navigant Corporate Advisors Ltd ("Manager to the Offer") has submitted to BSE a copy of Post Offer Advertisement to the Equity Shareholders of Prism Medico and Pharmacy Ltd ("Target Company"). PRISM MEDICO AND PHARMACY LTD. - 512217 - Offer Opening Public Announcement
Navigant Corporate Advisors Ltd ("Manager to the Offer") has submitted to BSE a copy of Offer Opening Public Announcement to the shareholders of Prism Medico and Pharmacy Ltd ("Target Company"). PRISM MEDICO AND PHARMACY LTD. - 512217 - Updates on Open Offer
Navigant Corporate Advisors Ltd ("Manager to the Offer") has submitted to BSE a copy of Submission of Advertisement of committee of independent directors in terms of Regulation 26 (7) of SEBI SAST (Regulations), 2011 of Prism Medico and Pharmacy Ltd ("Target Company"). PRISM MEDICO AND PHARMACY LTD. - 512217 - Outcome Of Meeting Of Committee Of Independent Directors For Open Offer Of Prism Medico And Pharmacy Limited.
The Committee of Independent Directors at its meeting held on today discussed, analysed and reviewed that the open offer given by Acquirers pursuant to Public Announcement dated 28th November, 2022, Detailed Public Statement dated 05th December, 2022 and Letter of Offer dated 07th February, 2023. The Committee of Independent Directors has concluded that open offer is fair and reasonable. PRISM MEDICO AND PHARMACY LTD. - 512217 - Clarification With Respect To Outcome Of The Board Meeting Held On 13Th February, 2023.
Dear Sir/Madam, With respect to the captioned subject it is hereby informed that a meeting of Board of Directors of the company was held on 13th February, 2023 for the approval of Unaudited Standalone Financial Results of the company for the quarter ended 31st December, 2022 alongwith Limited Review Report duly signed by the Auditors of the company. Whereas, in the outcome of Board Meeting filed by the company the date of Board Meeting has been inadvertently mentioned as 13th August, 2022 in place of 13th February, 2023. Therefore, the date shall be read as 13th February, 2023 instead of 13th August, 2022. Further the other details and information provided by the company remains the same. Kindly take on record the same and oblige. Thanking You.